Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Everolimus Stories

2012-03-20 02:24:35

NATICK, Mass., March 20, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 24-27 in Chicago. "Two-year results from the PLATINUM Workhorse clinical trial will provide important follow-up data on our next-generation PROMUS Element(TM) Everolimus-Eluting Platinum Chromium Stent," said Keith D. Dawkins, M.D., Global Chief Medical...

2012-03-01 07:30:00

NATICK, Mass., March 1, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the launch of the PROMUS Element(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. The product was recently approved by the Ministry of Health, Labor and Welfare. The PROMUS Element Stent System incorporates a platinum chromium (PtCr) alloy with an innovative stent design and an advanced catheter delivery system designed to provide physicians improved...

2012-02-01 07:30:00

NATICK, Mass., Feb. 1, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces first patient use and European market launch of the PROMUS Element(TM) Plus Everolimus-Eluting Platinum Chromium Coronary Stent System. The first patient implant in Europe using the new device was performed by Professor Antonio Colombo, M.D., Director of the Cardiac Catheterization Laboratory at Columbus Hospital and San Raffaele Hospital in Milan, Italy. The new stent system incorporates the...

2012-01-27 12:00:00

Drug helps keep cancer from progressing SILVER SPRING, Md., Jan. 27, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes in the kidney. Inlyta...

2011-12-22 08:00:00

ABBOTT PARK, Ill., Dec. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit((TM)) drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking). Claudication is the most common symptom in...

2011-12-08 16:58:45

Everolimus in combination with exemestane has shown promise for the treatment of breast cancer. "For postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, the addition of everolimus to exemestane markedly improves the duration of disease control," said Gabriel N. Hortobagyi, M.D., FACP, professor of medicine, chair of the department of breast medical oncology and director of the Multidisciplinary Breast Cancer Research Program at the University of Texas MD...

2011-12-08 16:32:18

In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer Center. The study, known as Breast Cancer Trials of Oral Everolimus (BOLERO-2),...

2011-12-08 08:30:00

ABBOTT PARK, Ill., Dec. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb(TM) bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System. Approximately 500 patients with coronary artery disease will be enrolled at about 40 investigational sites in Europe and New...

2011-12-07 17:34:00

EAST HANOVER, N.J., Dec. 7, 2011 /PRNewswire/ -- Updated results of a Phase III study of Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing (progression-free survival)(1). The study findings, which represent an additional five months of follow-up, were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium...

2011-11-30 10:45:17

Combination treatment with octreotide shows improved results in tumors associated with carcinoid syndrome Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center. Results of the international, randomized, placebo-controlled...